People taking Eli Lilly’s next-generation GLP-1 obesity drug retatrutide shed more pounds than any other weight-loss drug during a late-stage trial, the company said Thursday.
Patients using the highest dose of the once-weekly shot, over the course of 68 weeks, lost an average of up to 71.2 pounds at the end of the Phase 3 clinical trial.
